Home | Contact Us 

Online Catalog

View our online catalog.
For further information or for a quotation, call 1-510-475-0650 or email us at

How Can We Help You?
Click here to contact us!


Sepragen Corporation Announces The Addition Of A “Techno-Business” Advisory Board

Union City, CA, March 6, 2000 - Sepragen Corporation (OTC BB: SPGNU, SPGNA, SPGNW) today announced the formation of a “Techno-Business” advisory board to assist the Company in identifying and developing major opportunities in the biotech and nutraceutical industries for its platform separation technology.

The advisory board will be headed by Dr. Armin Ramel, formerly Vice President of Research for Scios, Inc. and Director of Process Development at Genentech and Hoffman La Roche. The members of the board also include:

  • Dr. John Finley, Senior Technology Principal at Kraft Foods, previously Director of New Project Development at Monsanto and Group Director at Nabisco;
  • Dr. Theodore Lioutas, VP of R&D at Brown-Forman Beverages Worldwide, previously Director of New Product Development at Tropicana;
  • Dr. Zdenek Kratky, Senior Advisor and Assistant Vice President for Nutrition Strategic Business Division at Nestle, Ltd; and
  • Dr. H.S. Muralidhar, Assistant VP of R&D and Director of Center of Excellence at Cargill Worldwide.
Vinit Saxena, Sepragen’s Chairman and CEO commented, “Sepragen’s platform separation technology enables the isolation and manufacture of high purity biological drugs and functional food ingredients necessary for the development of newer, healthier natural foods and nutraceuticals. The solutions provided by these key industry opinion leaders will certainly drive the direction of our growth path. We are excited about this team and look forward to their contributions.”

Sepragen Corporation develops and markets technology along with equipment and supplies for process chromatography applications. Sepragen has developed a number of patented applications that provide large market opportunities in the food and beverage industry, including debittering citrus juices, extracting isoflavone (plant estrogen) from soy, as well as extracting proteins from whey. The company holds over 14 issued patents relating to its core technology.

Return to News Archives main page

The statements in this release that relate to future events or performance, statements about growth, future regulatory clearances, levels of sales and market size and future manufacturing capacity and efficiencies are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to the development of markets for and commercial acceptance of the company's products and services, the availability of components, competitors' product introductions and other risks identified in the company's SEC filings. Actual results may differ from those described in these forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

Company | Products | News and Events | Contact Us | Terms and Conditions | Privacy Policy © 2020 Sepragen Corporation. All rights reserved. (510) 475-0650